The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

July 11, 2023 - The federal 340B Drug Pricing Program ("340B"), which is intended to help safety-net health care providers stretch their financial resources to reach more financially vulnerable ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

340B covered entities are expanding contracts with retail pharmacies that are increasingly located in counties with high rates of Medicare and Medicaid insurance coverage. The 340B Drug Pricing ...

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

Most government support programs provide benefits directly to people, whether it is SNAP (Supplemental Nutritional Assistance Program), TANF (Temporary Assistance for Needy Families), or housing ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

As a country, we are struggling to address what has become a tragic opioid epidemic gripping the nation. Our community health care providers are on the front lines of this crisis. While hospitals and ...

This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics. The 340B program has driven provider variation in the uptake of biosimilars ...